Assessment of Candidate Protein Expression in Breast Cancer Specimens
NCT ID: NCT00918892
Last Updated: 2022-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
460 participants
OBSERVATIONAL
2011-01-01
2021-09-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is looking at tumor tissue samples from patients who have undergone surgery for breast cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genetic and Protein Profiling in Normal and Cancerous Breast Tissue
NCT00083733
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Molecular Analysis of Breast Cancer
NCT00569049
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
NCT00898898
Identifying Genes That Predict Recurrence in Women With Breast Cancer Treated With Chemotherapy
NCT00897299
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine if candidate genes display differential expression between normal and cancer breast tissues.
OUTLINE: Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
gene expression analysis
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
immunohistochemistry staining method
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
laboratory biomarker analysis
Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of breast cancer
* Tissue samples available
* Samples are selected based on presence or absence of tumor receptors, (i.e.; estrogen, progesterone, and HER2 receptors) and grouped into following 4 categories:
* Estrogen receptor (ER)-positive/progesterone receptor (PR)-positive/HER2-negative
* ER-positive/PR-positive/ HER2-positive by FISH
* ER-negative/PR-negative/HER2-positive
* ER-negative/PR-negative/HER2-negative(triple negative or basal-type cancers)
PATIENT CHARACTERISTICS:
* Menopausal status not specified
PRIOR CONCURRENT THERAPY:
* Not specified
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Case Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stefanie Avril, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical trial summary from the National Cancer Institute's PDQ® database
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CASE1108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.